Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal.
Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics, announced its agreement to sell to Bayer AG for a purchase price of $1.5 billion and up to $500 million in success-based milestone payments.
After the closing of the acquisition, Bayer will own full rights to Vividion’s proprietary discovery platform, which includes three integrated, synergistic components: a novel chemoproteomic screening technology, an integrated data portal and a proprietary chemistry library. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.
Vividion Therapeutics’ platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high-value, traditionally undruggable targets in oncology and immunology.
The Cooley Team was led by Barbara Borden (Picture) and Karen Deschaine. Additional assistance was provided by Kay Chandler, Rowook Park, Matt Finan, Terren J. O’Connor, Alessandra Murata, Austin Holt, Kelsie Leigh Harris, Todd Gluth, Jeffrey Tolin, Megan Browdie, Nathan Cox, Ross Eberly, Daniel Lac, Natasha Leskovsek, Philip Mitchell, Gabrielle Whitehall and David Navetta.
The Wilson Sonsini team that advised Vividion on patent matters related to the transaction was led by Uale Taotafa and included Katrina Otrubova and Michael Hostetler.
Involved fees earner: Barbara Borden – Cooley LLP; Megan Browdie – Cooley LLP; Kay Chandler – Cooley LLP; Nathan Cox – Cooley LLP; Karen Deschaine – Cooley LLP; Ross Eberly – Cooley LLP; Matt Finan – Cooley LLP; Todd Gluth – Cooley LLP; Austin Holt – Cooley LLP; Daniel Lac – Cooley LLP; Kelsie Leigh Harris – Cooley LLP; Natasha Leskovsek – Cooley LLP; Philip Mitchell – Cooley LLP; Alessandra Murata – Cooley LLP; David Navetta – Cooley LLP; Terren O’Connor – Cooley LLP; Rowook Park – Cooley LLP; Jeffrey Tolin – Cooley LLP; Gabrielle Whitehall – Cooley LLP; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Katrina Otrubova – Wilson Sonsini Goodrich & Rosati; Uale Taotafa – Wilson Sonsini Goodrich & Rosati;
Clients: Vividion Therapeutics;